Cellectis posts $101.1 million nine-month loss
By Jon CuthbertKey points
- Cellectis (NASDAQ:CLLS) reported a nine-month 2026 net loss of $101.1 million, or $1.00 per share, compared with $41.3 million a year earlier.
- Revenue and other income declined to $19.9 million from $67.4 million, while cash and fixed-term deposits totaled $149 million at September 30.
- The company is shifting toward in vivo gene editing, targeting up to 70% workforce reductions and a cash runway into the second half of 2028 if its restructuring plan is fully implemented.
Cellectis (NASDAQ:CLLS) reported a nine-month 2026 net loss of $101.1 million, or $1 per share, compared with a $41.3 million loss, or $0.41 per share, in the same period of 2025.
Revenue and other income declined to $19.9 million from $67.4 million, mainly because of lower activity under its research collaboration agreement with AstraZeneca.
Research and development expenses increased to $108.8 million from $69.1 million, partly reflecting a $26.6 million facility impairment, $6.2 million in termination benefits and $2.1 million in costs related to closing clinical programs.
Cellectis held $149 million in cash, cash equivalents and fixed-term deposits at September 30, compared with $211 million at December 31, 2025, and expects funding into the second half of 2028 if its operating realignment is fully implemented, including planned workforce reductions of up to 70%.
The company has stopped enrollment in its lasme-cel and eti-cel programs and is advancing .HEAL-101, which achieved up to 70% APOC3 editing in humanized-liver mice, and .HEAL-201, which reduced plasma PCSK9 by more than 90%, with preliminary clinical data targeted for the second half of 2027 and first half of 2028, respectively.
Frequently asked questions (FAQ)
Editorial note: The $101.1 million loss covers the nine months ended September 30, 2026, not the third quarter alone. The .HEAL-101 and .HEAL-201 results are from preclinical animal studies, not human clinical trials. The projected cash runway depends on successful implementation of the restructuring plan.
